Trial 9L-17-8


A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogeneic stem cell transplantation (REACH 3)

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Biological Response Modifier, Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  George Yaghmour, M.D.
Other Trial Staff:  Simbiso Peresuh, Coordinator, John Lee, D.M., Suraj Chandwani, D.M., Christine Duran, Coordinator, Donna Fernando, Coordinator, Diana Oganyesyan, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.